MBX Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $2.50B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | – | $-0.50 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | Before market open | – | $-0.49 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | – | $-0.58 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | Before market open | – | $-0.71 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 17, 2025 | Before market open | – | $-0.47 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | – | – | – |
Press releases
Announcements MBX Biosciences filed with the SEC
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Pioneering Precision Peptides for Endocrine and Metabolic Diseases August 2026 Corporate Presentation
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ENDO 2026 Pioneering Precision Peptides for Endocrine and Metabolic Diseases June 12, 2026 EXHIBIT 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Pioneering Precision Peptides for Endocrine and Metabolic Diseases Obesity Day May 11, 2026 EXHIBIT 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Results of operations · Executive or director change · EX-99.1 to Form 8-K
MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Phase 2 Trial and Open-Label Extension Top-Line Results: Once-Weekly Canvuparatide in Adults with Hypoparathyroidism September 22, 2025 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Precision Endocrine Peptides Company Overview June 2025 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K